Plain-English plan summary
According to public Form 5500 filings published through the U.S. Department of Labor (DOL) Employee Benefits Security Administration (EBSA) via the EFAST2 system, Asklepios Biopharmaceuticals, Inc. 401(K) Plan is a benefit plan reported by Asklepios Biopharmaceutical, Inc. under EIN 20-0267834 and plan number 001. The latest loaded filing year is 2023. The filing reports 342 participants and $22,014,629 in end-of-year plan assets, where available in the loaded dataset.
Reported financial statement (2023 · Schedule H)
Net assets
- Total assets (EOY)
- $22,014,629
- Total liabilities (EOY)
- $0
- Net assets (EOY)
- $22,014,629
- Net assets (BOY)
- $11,347,627
Income & contributions
- Employer contributions
- $2,105,065
- Participant contributions
- $4,585,502
- Total contributions
- $7,969,053
- Total income / additions
- $11,100,257
Expenses & distributions
- Benefits paid
- $420,914
- Administrative expenses
- $12,341
- Total expenses
- $433,255
- Net increase / (decrease)
- $10,667,002